MDM2 inhibition in liposarcoma: a step in the right direction
Menée sur 20 patients atteints d'un liposarcome avec amplification MDM2, cette étude analyse le mécanisme d'action d'une petite molécule appelée RG7112, un antagoniste de MDM2
The assessment of systemic therapy in soft-tissue sarcoma has been hampered by the heterogeneity of over 50 different histological subtypes and the accompanying rarity of each subtype. Trials have typically involved a one-size-fits-all approach, with soft-tissue sarcomas being categorised as one disease. In specific histological subtypes, in which management has evolved separately, adjuvant and neoadjuvant systemic therapy has had a significant effect on survival. Conversely, for most subtypes, categorised as one group, adjuvant chemotherapy has no proven benefit...
The Lancet Oncology , commentaire en libre accès, 2011